Clinical trials: Normal Population
Atopic Dermatitis
Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
It is a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial to evaluate the efficacy of QLM3003 ointment at week 8 based on the primary endpoint (EASI 75) and key secondary endpoint…
- Trial name
- NCT06880276
- Testing
- 1.5% QLM3003 ointment, 2% QLM3003 ointment
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old
The purpose of this study is to assess the efficacy and safety of pimecrolimus cream 1% in relation to the improvement of pruritus in pediatric patients (2- to 11- year-old) with mild to moderate atopic dermatitis.
- Trial name
- NCT00510003
- Testing
- Pimecrolimus
- Where
- Spain
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Hepatic Impairment, Healthy
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy…
- Trial name
- NCT06908954
- Testing
- Palovarotene
- Where
- 4 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Ipsen
Diabetic Kidney Disease
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
The primary objective of this study is to evaluate the pharmacokinetics (PK) of selonsertib in participants with impaired hepatic function relative to matched, healthy controls.
- Trial name
- NCT02509624
- Testing
- Selonsertib
- Where
- 5 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Leiomyoma
Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap
The study is performed to assess the efficacy and safety of different doses of BAY1002670 in subjects with uterine fibroids. The dose-response relationship will be evaluated.
- Trial name
- ASTEROID 1 (NCT02131662)
- Testing
- BAY1002670
- Where
- 105 sites in United States, Belgium and 11 more
- Volunteers
- 309 people
- Sponsor
- Bayer
Atopic Dermatitis
A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of 2 doses of S-777469 in patients with atopic dermatitis.
- Trial name
- NCT00703573
- Testing
- S-777469 400 mg, S-777469 800 mg
- Where
- 33 sites in United States
- Volunteers
- 209 people
- Sponsor
- Shionogi
Healthy Volunteers
Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects
The purpose of this study is assess the pharmacokinetics and safety of M834 and Orencia ® following administration of a single-dose in healthy volunteers.
- Trial name
- NCT02923583
- Testing
- M834, US-Sourced Orencia®, EU-Sourced Orencia®
- Where
- 2 sites in United Kingdom
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Momenta Pharmaceuticals, Inc.
Rheumatoid Arthritis
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis
- Trial name
- ADMYRA (NCT02744755)
- Testing
- Adalimumab - GP2017, Adalimumab - US licensed Humira
- Where
- 83 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Sandoz
Tuberous Sclerosis, Angiofibroma
Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)
- Conditions
- Tuberous Sclerosis, Angiofibroma, Hypomelanotic Macule, Plaque
- Trial name
- NCT02635789
- Testing
- NPC-12G gel
- Where
- Japan
- Volunteers
- 62 people
- Sponsor
- Nobelpharma
Psoriasis, Plaque Psoriasis
A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis
This is a double-blind, multicenter, vehicle-controlled, parallel group comparison study to determine and compare the efficacy and safety of HBP Lotion 0.05% and Vehicle Lotion applied twice daily for two weeks in subjects with…
- Trial name
- NCT01610596
- Testing
- Halobetasol Propionate Lotion 0.05%
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Therapeutics, Inc.
Sjogren's Disease
ONO-4915 in Patients With Primary Sjogren's Disease
To evaluate the efficacy and safety of ONO-4915 in patients with primary Sjogren's disease
- Trial name
- NCT07823790
- Testing
- ONO-4915
- Volunteers
- 60 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Plaque Psoriasis, Psoriasis
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.
- Conditions
- Plaque Psoriasis, Psoriasis, Skin Diseases
- Trial name
- IMPACT-PS (NCT03832738)
- Testing
- JTE-451 Tablets
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 152 people
- Sponsor
- Shionogi Inc.
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate and have had an inadequate response to a…
- Trial name
- OSKIRA - 3 (NCT01197755)
- Testing
- fostamatinib
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 323 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe
The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.
- Trial name
- NCT01890473
- Testing
- Abatacept
- Where
- 25 sites in United States, Argentina and 3 more
- Volunteers
- 356 people
- Sponsor
- Bristol-Myers Squibb
Normal Healthy Subject Population
Comparison of Prilosec OTC® Versus Zegerid® for Gastric Acid Suppression
The purpose of this study is to compare Prilosec OTC® and Zegerid® in their effects on gastric acid suppression.
- Trial name
- NCT00808769
- Testing
- Zegerid®, Prilosec OTC®
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)
This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy.
- Trial name
- NCT00928512
- Testing
- Secukinmab
- Where
- 58 sites in United States, Belgium and 9 more
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.
The purpose of this study is to determine whether QAW039 is safe and has beneficial effects in people who have moderate to severe atopic dermatitis (AD).
- Trial name
- NCT01785602
- Testing
- QAW039
- Where
- 18 sites in Australia, Austria and 6 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Arthritis, Rheumatoid
Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis…
- Trial name
- CONDOR (NCT00141102)
- Testing
- Celecoxib, Diclofenac + Omeprazole
- Where
- 194 sites in Belgium, Brazil and 30 more
- Volunteers
- 4,484 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Idiopathic Urticaria
Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
The purpose of the study is to compare the efficacy, safety, tolerability, and immunogenicity of ADL-018 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1…
- Trial name
- NCT05774639
- Testing
- Omalizumab Injection, Xolair Prefilled Syringe
- Where
- 6 sites in United States, India and 1 more
- Volunteers
- 600 people
- Sponsor
- Kashiv BioSciences, LLC
Infections, Herpesviridae
VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.
Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.
- Trial name
- NCT00116844
- Testing
- Valaciclovir
- Where
- 17 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.